Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma

American Journal of Clinical Pathology

Volumn 134, Issue 2, 2010, Pages 278-281

  Durnick, David K ^a   Law, Mark E ^a   Maurer, Matthew J ^a   Natkunam, Yasodha ^b   Levy, Ronald ^b   Lossos, Izidore S ^c   Kurtin, Paul J ^a   McPhail, Ellen D ^a  

^a MAYO CLINIC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

BCL6; Diffuse large B cell lymphoma; LMO2; t(14; 18)IgH BCL2

Indexed keywords

BIOLOGICAL MARKER; HYBRID PROTEIN; IGH BCL2 FUSION PROTEIN; LMO 2 PROTEIN; MEMBRANE PROTEIN; PROTEIN BCL 6; UNCLASSIFIED DRUG;

ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 16; DNA-BINDING PROTEINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, BCL-2; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; METALLOPROTEINS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-BCL-6; TISSUE ARRAY ANALYSIS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77955621172     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPATUP1D0HGCUG     Document Type: Article

References (17)

1. Stein H, Warnke RA, Chan WC, et al. Diffuse large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:233-237.
2. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74. (Pubitemid 34101731)
3. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991-9996. (Pubitemid 37087056)
4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
5. Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood. 2007;109:1636-1642. (Pubitemid 46239598)
6. Harris NL, Swerdlow SH, Jaffe ES, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:220-226.
7. Iqbal J, Sanger WG, Horsman DE, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004;165:159-166.
8. Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21:2332-2343. (Pubitemid 350011706)
9. Warren AJ, Colledge WH, Carlton MB, et al. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell. 1994;78:45-57.
10. Alizadeh AA, Elsen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
11. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828-1837.
12. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008;26:447-454.
13. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med. 1994;331:74-80. (Pubitemid 24984701)
14. Kramer MHH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162. (Pubitemid 28492322)
15. Shustik J, Han G, Farinha P, et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica. 2010;95:96-101.
16. Barrans SL, O'Connor SJM, Evans PAS, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol. 2002;117:322-332.
17. Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol. 1998;9:55-61.